CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

Abstract Our previous studies revealed that the level of activated circulating endothelial cells (aCECs) was correlated with the progression‐free survival (PFS) in antiangiogenesis therapy. Anlotinib displayed affirmatory efficacies in several clinical trials of non‐small‐cell lung cancer (NSCLC). T...

Full description

Bibliographic Details
Main Authors: Zhujun Liu, Jing Wang, Zhaoting Meng, Xinyue Wang, Cuicui Zhang, Tingting Qin, Jinliang Chen, Xiangli Jiang, Liuchun Wang, Li Lin, Xiaoling Zhang, Peng Chen, Chun Huang, Richeng Jiang, Kai Li
Format: Article
Language:English
Published: Wiley 2018-07-01
Series:Cancer Medicine
Subjects:
angiogenesis
anlotinib
CD105
CD31
endothelial cells
non‐small‐cell lung cancer
Online Access:https://doi.org/10.1002/cam4.1584

Internet

https://doi.org/10.1002/cam4.1584

Similar Items